We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > clinical studies

News List

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies americanpharmaceuticalreview
September 03, 2018
Pfizer announced it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).
AmpTec and CMC Pharma Close Consulting Agreement about API-mRNA Production for IND/CTA Use in Early b3cnewswire
February 22, 2017
AmpTec GmbH is an ISO 13485:2009 certified Provider of High Quality synthetic nucleic acids for worldwide leading companies in the fields of molecular diagnostics, biotechnology and therapeutic applications.
RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma b3cnewswire
January 09, 2017
The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma Foundation Annual Conference, describes positive findings from non-clinical studies...